Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,805 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07058688RecruitingPhase 2
Testing a new drug for Alzheimer's (NTRX-07)
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
BrnoAges 65–80 - NCT07062198RecruitingPhase 3
Metabolic supplement for Alzheimer's disease
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
AlanyaAges 50 years+ - NCT07055373Recruiting
Nerve stimulation for chronic whiplash pain
This trial tests if a gentle nerve stimulation device on the ear can reduce neck pain and disability in people with long-term whiplash symptoms. It aims to find a safe, non-drug option for pain relief.
Calgary, AlbertaAges 18–65 - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT07031687Recruiting
A new brain stimulation study for early Alzheimer's
This study tests a non-invasive brain stimulation method (temporal interference stimulation) to see if it can improve memory in people with early signs of Alzheimer's disease. It aims to understand how the stimulation affects brain function.
Sanya, HainanAges 60–80 - NCT07022522Recruiting
Brain stimulation frequencies for impulse control in Parkinson's
This study tests whether stimulating specific parts of the brain's subthalamic nucleus at different frequencies can improve control over unwanted movements or impulses in people with Parkinson's disease. If you are planning to have DBS surgery, this trial may help find a better way to use the device.
Beijing, Beijing MunicipalityAges 40–80 - NCT03851523Recruiting
Tracking memory changes in people with early Alzheimer’s symptoms
This study follows people over time to better understand how memory and thinking complaints progress in early Alzheimer’s disease (from “subjective cognitive decline” to mild cognitive problems). It may help researchers understand who is likely to decline and how symptoms change, which could support future treatments.
Barcelona, CataloniaAges 45 years+ - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT06992804RecruitingEarly Phase 1
Light therapy and lecanemab for mild Alzheimer's
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
BeijingAges 50–90 - NCT06827678Recruiting
Study of Alzheimer’s disease using brain scans in China
This study uses brain imaging to understand early changes in Alzheimer's disease. It may help people with or without memory problems learn more about their condition and support future treatments.
ShanghaiAges 45–90 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06923007Recruiting
Vagus nerve stimulation for Alzheimer's disease
This trial tests if a nerve stimulation device can help people with mild to moderate Alzheimer's. It is for patients aged 50 to 80 who are on a stable medication.
BeijingAges 50–80 - NCT06963879Enrolling by invitation
Video game test and treatment for Alzheimer's disease
This study uses interactive video games to help diagnose and potentially treat early-stage Alzheimer's disease or mild cognitive impairment. It is testing whether these games can improve thinking skills.
Mataró, BarcelonaAges 50 years+ - NCT06953830Enrolling by invitation
Measuring spleen stiffness in veterans with fatty liver disease
This study tests a new way to measure spleen stiffness in veterans with metabolic-dysfunction fatty liver disease. It may help doctors better understand and monitor this condition without invasive procedures.
Columbia, South CarolinaAges 18 years+ - NCT06956300Recruiting
TMS to help with thinking and memory in aging
This study uses a noninvasive brain stimulation technique called TMS to see if it can slow cognitive decline in older adults who are healthy or have very early signs of Alzheimer's disease. It aims to improve memory and thinking.
Boston, MassachusettsAges 40–99 - NCT06948929Recruiting
Gut health supplement trial for Alzheimer's patients in Hong Kong
This trial tests whether a daily supplement of friendly bacteria and prebiotics (called a synbiotic) can help people with Alzheimer's. It looks at how the supplement affects thinking, behavior, and daily life over time.
ShatinAges 60–90 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06918145Enrolling by invitation
LVA surgery for Alzheimer's disease
This study tests a surgery called lymphaticovenous anastomosis (LVA) as a possible treatment for Alzheimer's disease. The surgery connects tiny lymph vessels to veins to help clear waste from the brain.
Beijing, Beijing MunicipalityAges 50–85 - NCT06880406Recruiting
Study of cell energy in Alzheimer's and other dementias
This study looks at how energy production in cells (mitochondria) differs in people with Alzheimer's or other dementias compared to healthy volunteers. It involves a one-time spinal tap to collect fluid for analysis.
Nice, PACAAges 18 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,805 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.